Clinical effect of three-dimensional conformal radiotherapy combined w ith concurrent chemotherapy for the treatment of m iddle and advanced esophageal cancer
LIN Jia WANG Ji-yu XU Hong-wei
Department of Radiotherapy,Jieyang People′s Hospital,Guangdong Province,Jieyang 522000,China
Abstract:ObjectiveTo explore the clinical effect of three-dimensional conformal radiotherapy combined with concurrent chemotherapy for the treatment of middle and advanced esophageal cancer.MethodsForty-five patients with middle and advanced esophageal cancer admitted into our hospital from March 2016 to June 2017 were selected.They were divided into the control group (n=23)and observation group (n=22)according to an envelope randomization grouping method.Three-dimensional conformal radiotherapy was performed in the control group,while in the observation group,three-dimensional conformal radiotherapy combined with concurrent chemotherapy was adopted.The short-term and long-term efficacy,adverse reactions,survival rate,and survival time of the two groups after the corresponding treatment were observed.ResultsIn the observation group,the short-term and long-term total effectiveness rate was 95.45%and 90.91%respectively and 3-month and 6-mongh survival rate was 95.45%and 81.82%respectively in the observation group,which was higher than that in the control group respectively,and the incidence of adverse reactions was 9.09%in the observation group,which was lower than that in the control group,and the survival time was(19.85±5.34)months,which was longer than that in the control group (P<0.05).ConclusionThree-dimensional conformal radiotherapy combined with concurrent chemotherapy is obvious in middle and advanced esophageal cancer and can prolong survival time.
林佳; 王继宇; 许宏伟. 三维适形放疗联合同期化疗治疗中晚期食管癌的临床效果[J]. 中国当代医药, 2018, 25(17): 81-83.
LIN Jia; WANG Ji-yu; XU Hong-wei. Clinical effect of three-dimensional conformal radiotherapy combined w ith concurrent chemotherapy for the treatment of m iddle and advanced esophageal cancer. 中国当代医药, 2018, 25(17): 81-83.